S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CLDX · Celldex Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Celldex Therapeutics Inc (CLDX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$29.36
-0.94
(-3.09%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$29.36
$29.31
$30.57
52-WEEK RANGE
$29.36
$22.10
$45.14
What's happening
- CLDX is down 3.09% today, trading at $29.36. — Live quote
- Volume today (51,289) is well below its 3-month average of 1,333,140. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.94 actual vs. $-1.08 estimated (+12.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 12
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CLDX
+11.52%
vs S&P 500
-1.25%
1-YEAR RETURN
CLDX
+9.47%
vs S&P 500
-5.09%
6-MONTH RETURN
CLDX
-10.54%
3-MONTH RETURN
CLDX
-15.06%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.94
Est. $-1.08
BEAT +12.8%
2026-04-26 (Q1 2026)
$-1.18
Est. $-1.16
MISS -1.6%
2026-01-26 (Q4 2025)
$-1.22
Est. $-1.03
MISS -18.6%
2025-10-26 (Q3 2025)
$-1.01
Est. $-0.92
MISS -9.9%
Valuation Measures & Ratios
Enterprise Value4$2.28B
Forward P/E5—
PEG Ratio6-0.15
Price / Sales (TTM1)14699.44
Price / Book74.09
EV4 / Revenue14399.09
EV4 / EBITDA—
Profit Margin-147787.97%
Operating Margin-159627.22%
Return on Equity (ROE8)-52.35%
Return on Assets (ROA9)-47.61%
Avg Volume (3M)1,333,140
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.91B | $2.11B | $1.72B | $1.36B | $1.20B |
| P/E | -10.54 | -8.25 | -7.82 | -7.20 | -7.31 |
| Price/Sales | — | — | — | 190.71 | 184.01 |
| Price/Book | 4.07 | 4.63 | 2.87 | 2.07 | 1.71 |
| EV/Revenue | — | — | — | 187.47 | 181.39 |
| EV/EBITDA | -9.57 | -7.39 | -6.75 | — | — |
| ROE | -38.60% | -56.14% | -36.69% | -28.74% | -23.41% |
| ROA | -35.26% | -50.10% | -33.86% | -27.20% | -22.25% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,006,720
Change from Prior Settlement+22.94%
% of Float—
Days to Cover (Short Ratio)3.81
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +9.5%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-09-22; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -97.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -147788.0%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CLDX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.0K | $15.0K | — | $730.0K | $695.0K | $3.2M | $2.5M | $156.0K |
| Operating income | -$80.6M | -$84.4M | -$73.6M | -$63.9M | -$62.7M | -$52.1M | -$46.3M | -$40.6M |
| Net income | -$73.5M | -$78.7M | -$67.0M | -$56.6M | -$53.8M | -$42.1M | -$35.8M | -$32.8M |
| EPS (diluted) | $-0.94 | $-1.18 | $-1.01 | $-0.85 | $-0.81 | $-0.64 | $-0.54 | $-0.56 |
| EPS (basic) | $-0.94 | $-1.18 | $-1.01 | $-0.85 | $-0.81 | $-0.64 | $-0.54 | $-0.56 |
| Operating margin | -$366.5K | -$562.9K | — | -$8.7K | -$9.0K | -$1.6K | -$1.9K | -$26.0K |
| Net margin | -$334.1K | -$524.6K | — | -$7.8K | -$7.7K | -$1.3K | -$1.4K | -$21.0K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $782.3M | $511.3M | $583.0M | $648.4M | $692.4M | $739.5M | $792.3M | $823.2M |
| Total liabilities | $67.8M | $55.0M | $55.8M | $50.1M | $37.0M | $36.5M | $45.3M | $37.3M |
| Stockholders' equity | $714.6M | $456.2M | $527.2M | $598.4M | $655.4M | $703.0M | $747.0M | $785.9M |
| Total current assets | $724.9M | $459.2M | $534.7M | $604.3M | $648.4M | $693.8M | $747.2M | $778.8M |
| Total current liabilities | $61.3M | $51.5M | $51.0M | $46.5M | $33.0M | $32.0M | $39.5M | $32.1M |
| Cash & equivalents | $47.5M | $35.7M | $28.9M | $36.0M | $23.0M | $17.1M | $28.4M | $36.4M |
| Marketable securities (current) | $670.1M | $415.7M | $489.7M | $547.2M | $607.3M | $656.2M | $696.9M | $719.6M |
| Property, plant & equipment | $9.8M | $7.4M | $5.3M | $4.8M | $4.4M | $4.6M | $4.3M | $4.2M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M |
| Other non-current assets | $15.4M | $15.4M | $13.4M | $9.4M | $9.3M | $10.4M | $9.7M | $9.7M |
| Accounts payable | $14.7M | $10.4M | $1.2M | $4.3M | $2.1M | $3.4M | $3.3M | $1.1M |
| Accrued liabilities | $43.9M | $38.4M | $47.0M | $39.7M | $28.4M | $25.5M | $33.8M | $28.2M |
| Other current liabilities | $1.2M | $1.2M | $1.2M | $930.0K | $930.0K | $1.7M | $942.0K | $1.4M |
| Other non-current liabilities | $3.1M | $3.1M | $4.0M | $2.5M | $2.5M | $2.5M | $3.5M | $3.5M |
| Common stock & paid-in capital | $79.0K | $67.0K | $67.0K | $66.0K | $66.0K | $66.0K | $66.0K | $66.0K |
| Retained earnings | -$1.97B | -$1.89B | -$1.81B | -$1.73B | -$1.67B | -$1.61B | -$1.56B | -$1.51B |
| Accumulated other comprehensive income (loss) | $1.3M | $2.5M | $3.6M | $3.8M | $3.3M | $3.6M | $3.3M | $5.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.4M | -$65.6M | -$63.9M | -$48.6M | -$44.0M | -$54.4M | -$32.5M | -$55.3M |
| Investing cash flow | -$255.5M | $72.1M | $55.4M | $60.8M | $49.9M | $43.0M | $24.0M | $47.8M |
| Financing cash flow | $324.7M | $327.0K | $1.3M | $774.0K | $63.0K | $202.0K | $386.0K | $1.2M |
| Free cash flow | -$60.6M | -$67.2M | -$65.2M | -$49.1M | -$44.7M | -$54.6M | -$33.2M | -$55.9M |
| Capital expenditures | $3.2M | $1.6M | $1.3M | $440.0K | $728.0K | $265.0K | $756.0K | $545.0K |
| Depreciation & amortization | $902.0K | $854.0K | $816.0K | $824.0K | $873.0K | $867.0K | $819.0K | $786.0K |
| Share-based compensation | $8.4M | $8.5M | $8.9M | $8.8M | $9.2M | $9.3M | $9.8M | $9.6M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Purchases of investments | $402.9M | $59.6M | $54.8M | $55.6M | $122.3M | $151.8M | $129.2M | $100.1M |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M |
| Net income | -$258.8M | -$157.9M | -$141.4M | — | — |
| EPS (diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| EPS (basic) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| Operating margin | -$18.6K | -$2.8K | -$2.2K | -$4.9K | -$1.5K |
| Net margin | -$16.7K | -$2.2K | -$2.1K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M |
| Stockholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M |
| Total current assets | $534.7M | $747.2M | $431.7M | $317.7M | $410.8M |
| Total current liabilities | $51.0M | $39.5M | $31.1M | $18.6M | $16.5M |
| Cash & equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M |
| Marketable securities (current) | $489.7M | $696.9M | $388.8M | $275.5M | $369.1M |
| Property, plant & equipment | $5.3M | $4.3M | $4.1M | $3.7M | $3.6M |
| Goodwill | — | — | — | — | — |
| Intangible assets | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M |
| Other non-current assets | $13.4M | $9.7M | $107.0K | $104.0K | $104.0K |
| Accounts payable | $1.2M | $3.3M | $3.5M | $3.3M | $1.2M |
| Accrued liabilities | $47.0M | $33.8M | $22.0M | $12.8M | $12.0M |
| Other current liabilities | $1.2M | $942.0K | $4.0M | $990.0K | $1.6M |
| Other non-current liabilities | $4.0M | $3.5M | $4.4M | $5.3M | $7.4M |
| Common stock & paid-in capital | $67.0K | $66.0K | $56.0K | $47.0K | $47.0K |
| Retained earnings | -$1.81B | -$1.56B | -$1.40B | -$1.26B | -$1.14B |
| Accumulated other comprehensive income (loss) | $3.6M | $3.3M | $3.3M | $1.3M | $1.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M |
| Investing cash flow | $209.1M | -$290.1M | -$105.8M | $89.9M | -$216.2M |
| Financing cash flow | $2.4M | $441.4M | $218.5M | $4.1M | $272.4M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M | -$62.2M |
| Capital expenditures | $2.7M | $1.9M | $1.8M | $1.8M | $1.2M |
| Depreciation & amortization | $3.4M | $3.2M | $3.0M | $2.9M | $3.1M |
| Share-based compensation | $36.2M | $34.2M | $23.9M | $15.6M | $9.0M |
| Purchases of investments | $384.5M | $789.9M | $424.6M | $189.0M | $389.9M |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CLDX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers84.4%
Shares Outstanding77,840,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 9,543,671 | $355.1M | 12.26% | +11.5% | 2026-08-14 |
| BlackRock, Inc. | 7,002,530 | $260.6M | 9.00% | +30.4% | 2026-08-07 |
| Kynam Capital Management, LP | 5,322,908 | $198.1M | 6.84% | -8.9% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4,685,223 | $174.3K | 6.02% | +124.6% | 2026-08-14 |
| State Street Corp | 3,900,427 | $145.1M | 5.01% | +39.1% | 2026-08-07 |
| FMR LLC | 3,722,888 | $138.5M | 4.78% | -0.7% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,464,831 | $128.9M | 4.45% | +17.0% | 2026-06-30 |
| Deep Track Capital, LP | 2,939,151 | $109.4M | 3.78% | +128.9% | 2026-08-14 |
| Logos Global Management LP | 2,100,000 | $78.1M | 2.70% | +366.7% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,022,226 | $75.3M | 2.60% | +19.8% | 2026-08-12 |
| Eversept Partners, LP | 1,785,941 | $66.5M | 2.29% | -0.1% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,615,343 | $60.1M | 2.08% | +63.4% | 2026-08-14 |
| Commodore Capital LP | 1,350,000 | $50.2M | 1.73% | -49.9% | 2026-08-14 |
| Bellevue Group AG | 1,200,000 | $44.7M | 1.54% | +0.0% | 2026-08-13 |
| BAKER BROS. ADVISORS LP | 1,182,611 | $44.0M | 1.52% | +77.7% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 1,170,787 | $43.6M | 1.50% | -6.6% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 1,073,985 | $40.0M | 1.38% | +1.4% | 2026-08-11 |
| AMERICAN CENTURY COMPANIES INC | 1,042,395 | $38.8M | 1.34% | +21.7% | 2026-08-12 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1,037,000 | $38.6M | 1.33% | +0.0% | 2026-08-14 |
| Novo Holdings A/S | 1,025,000 | $38.1M | 1.32% | -14.6% | 2026-08-14 |
| Elmind Capital, LP | 990,000 | $36.8M | 1.27% | +14.5% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 989,442 | $36.8M | 1.27% | +0.0% | 2026-08-14 |
| Fisher Asset Management, LLC | 985,677 | $36.7M | 1.27% | -2.8% | 2026-08-04 |
| Pictet Asset Management Holding SA | 917,408 | $34.1M | 1.18% | -0.7% | 2026-07-30 |
| Foresite Capital Management VI LLC | 879,713 | $32.7M | 1.13% | +178.5% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-08-13 to 2026-01-02
Recent transactions
- Most recent: Martin Samuel Bates (SVP AND CFO) — Option exercise of 4,817 shares on 2026-01-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO | Option exercise | 2026-01-02 | 4,817 |
| PEPIN RONALD | SR. VP & CBO | Option exercise | 2025-12-15 | 8,333 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | Open market sale | 2025-12-04 | 4,166 |
| Wright Richard M. | Reporting person | Option exercise | 2025-11-13 | 6,876 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-01-02 | Martin Samuel Bates | SVP AND CFO | Option exercise | 4,817 | $10.38 |
| 2025-12-15 | PEPIN RONALD | SR. VP & CBO | Option exercise | 8,333 | $9.02 |
| 2025-12-15 | PEPIN RONALD | SR. VP & CBO | Option exercise | 11,000 | $2.78 |
| 2025-12-04 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Open market sale | 4,166 | $29.09 |
| 2025-11-13 | Wright Richard M. | Reporting person | Option exercise | 6,876 | $9.02 |
| 2025-11-13 | Wright Richard M. | Reporting person | Option exercise | 26,672 | $10.38 |
| 2025-11-13 | Wright Richard M. | Reporting person | Option exercise | 15,750 | $22.48 |
| 2025-11-13 | Wright Richard M. | Reporting person | Open market sale | 49,298 | $24.00 |
| 2025-08-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Open market sale | 341 | $23.95 |
| 2025-08-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Open market sale | 430 | $25.41 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:28 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-15 | 8-K | 2026-07-10 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
Recent news
Headlines about CLDX (Celldex Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Understanding Momentum Shifts in (CLDX)
Stock Traders Daily · 2026-10-21 -
CLDX Nov 2026 30.000 call (CLDX261120C00030000) interactive stock chart
Yahoo Finance UK · 2026-10-21 -
CLDX Nov 2026 41.000 call (CLDX261120C00041000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
HC Wainwright sets USD 64.00 target for Celldex Therapeutics stock
AD HOC NEWS · 2026-10-20 -
CLDX Dec 2026 65.000 call (CLDX261218C00065000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-20 -
CLDX Dec 2026 65.000 call (CLDX261218C00065000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
CLDX Dec 2026 43.000 call (CLDX261218C00043000) interactive stock chart
Yahoo Finance UK · 2026-10-19 -
Learn Why The Bull Case For Celldex Therapeutics Stock Could Change Following Shareholder Investigation
Simply Wall Street · 2026-10-19
No headlines in this category right now — try “All”.